Dermatology

Pharma

Galderma doubles Nemluvio peak sales outlook to $4B-plus

The update follows what Galderma’s CEO described as an “outstanding launch trajectory” for the Dupixent competitor in its first full year on the market.

Angus Liu Mar 5, 2026 11:20am

Veradermics locks in $256M IPO, shares spike

Feb 5, 2026 10:01am

Arcutis, Kowa part ways on Zoryve marketing partnership

Jan 26, 2026 11:45am

JPM26: Leo Pharma sharpens its eye for dermatology dealmaking

Jan 13, 2026 2:45pm

cost cutting restructuring savings reduce spend

InflaRx charts layoffs, cost cuts to lift lead asset's prospects

Jan 8, 2026 11:03am

InflaRx may find path forward for COVID drug in skin disorder

Jan 2, 2026 10:25am